Genitourinary oncology program

泌尿生殖肿瘤学项目

• 批准号: 6211791
• 负责人: MARC A. SHUMAN
• 金额: --
• 依托单位: UNIVERSITY OF CALIFORNIA, SAN FRANCISCO
• 依托单位国家: 美国
• 财政年份: 1999
• 资助国家: 美国
• 起止时间: 1999-08-05 至 2002-07-31
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/6211791
• 关键词: angiogenesis; bladder neoplasm; clinical research; human subject; kidney neoplasms; neoplasm /cancer diagnosis; neoplasm /cancer genetics; neoplasm /cancer therapy; neoplastic process; prostate neoplasms

Description: (Applicant's Description) The Genitourinary (GU) Cancer Program is an interdisciplinary group that includes members from 10 academic departments: Anatomy, Biochemistry & Biophysics, Cellular & Molecular Pharmacology, Laboratory Medicine, Medicine, Microbiology & Immunology, Pathology, Radiation Oncology, Radiology, and Urology working together on cancer of the bladder, kidney, and prostate. The common interest that spurred formation of this Program and fuels its existence is the utilization of basic research in genetic, molecular, and cellular biology to understand the origins and mechanisms of progression of genitourinary cancers, and to use this knowledge to develop novel approaches to their diagnosis and treatment. Current and developing research is focused on the molecular pathology of prostate cancer-induced angiogenesis, stromal-epithelial interactions in prostate cancer, and the genetic basis for hormone refractory prostate cancer (HRPC). Major foci in clinical research are the use of immunotherapy and anti-angiogenic treatments in HRPC, and developing novel MRI/MRSI technology for evaluating prostate cancer. Monthly Program conferences are highly interactive and very well attended by faculty, post-docs, and graduate students. From these meetings, collaborations have developed and grown at several levels. Several NIH RO1 grants and a Protease in Cancer PPG, as well as major grants from CaP Cure for clinical research, provide considerable resources for the Program.

描述：（申请人描述）泌尿生殖 (GU) 癌症项目是一个跨学科小组，包括来自 10 个学术部门的成员：解剖学、生物化学与生物物理学、细胞与分子药理学、实验医学、医学、微生物学与免疫学、病理学、放射肿瘤学、放射科和泌尿科共同研究膀胱癌、肾癌和前列腺癌。 促使该计划形成并推动其存在的共同兴趣是利用遗传、分子和细胞生物学的基础研究来了解泌尿生殖系统癌症的起源和进展机制，并利用这些知识开发治疗泌尿生殖系统癌症的新方法。诊断和治疗。 当前和正在开展的研究重点是前列腺癌诱导的血管生成的分子病理学、前列腺癌中的基质-上皮相互作用以及激素难治性前列腺癌（HRPC）的遗传基础。 临床研究的主要焦点是在 HRPC 中使用免疫疗法和抗血管生成治疗，以及开发用于评估前列腺癌的新型 MRI/MRSI 技术。 每月的项目会议互动性很强，教师、博士后和研究生都踊跃参加。 通过这些会议，合作在多个层面上得到了发展和壮大。 NIH RO1 的多项资助和癌症 PPG 中的蛋白酶，以及 CaP Cure 用于临床研究的主要资助，为该计划提供了大量资源。